Logo

UCB Reports P-III Open-Label Extension Study Results of Fintepla (fenfluramine) for Lennox-Gastaut Syndrome

Share this
UCB Reports P-III Open-Label Extension Study Results of Fintepla (fenfluramine) for Lennox-Gastaut Syndrome

UCB Reports P-III Open-Label Extension Study Results of Fintepla (fenfluramine) for Lennox-Gastaut Syndrome

Shots:

  • The P-III OLE study evaluating Fintepla (0.2/0.7mg/kg/day) added to an anti-epileptic treatment regimen vs PBO in 247 patients aged 2-35yrs. with LGSat 65 study sites in North America, the EU & Australia
  • The results showed a reduction in the frequency of multiple seizure types associated with a drop or fall for 15mos. incl. tonic & generalized tonic-clonic seizures & was well tolerated during a median treatment duration of 364 days. The results were published in Epilepsia
  • Median percentage change in monthly drop seizure frequency (-28.6% vs -50.5%) @15mos. with 31.1% experiencing a ≥50% reduction, change in frequency of all motor seizures was 45.9%. GTCS & tonic seizures were most responsive to treatment with median reductions over the entire OLE of -48.8% & -35.8%

Ref: PRNewswire | Image: UCB

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions